Compare BridgeBio Pharma Inc (BBIO) vs Trade Desk Inc (TTD) Price & Performance

BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.

Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.

The Trade Desk (TTD) trades at $19.79, up 1.33% with a mixed technical picture showing bullish overall signals but bearish moving averages. Fundamentally, the company maintains strong profitability with 77.83% gross margins and 14.57% net income margin, though revenue growth has slowed from 25% to 12% guidance. Recent developments include new data partnerships in Japan and board appointments, while settling the Publicis dispute removes a key headwind.

TTD presents a value opportunity trading below consensus targets with strong cash flow generation, but faces growth deceleration and competitive pressures. The stock's 52% decline year-to-date reflects market concerns about market share loss to walled gardens, though aggressive share repurchases and attractive valuation multiples support potential upside if growth stabilizes.